Acneiform Eruption Induced by Cetuximab by Claudia Cotena et al.
246
Acneiform Eruption Induced by Cetuximab
Claudia Cotena, Paolo Gisondi, Chiara Colato1, Giampiero Girolomoni
Department of Biomedical and Surgical Science, Section of Dermatology and 
Venereology, University of Verona; 1Department of Pathology, Azienda Ospedaliera of 
Verona, Verona, Italy 
Corresponding author:
Paolo Gisondi, MD
Department of Biomedical and Surgical Science





Received: July 5, 2007
Accepted: October 9, 2007
SUMMARY Cetuximab is a recombinant human/mouse chimeric 
monoclonal antibody that targets the extracellular domain of the 
epidermal growth factor receptor (EGFR). Cetuximab is approved 
by the US Food and Drug Administration for the treatment of 
EGFR-expressing metastatic colorectal cancer as monotherapy 
in patients who are intolerant to irinotecan-based chemotherapy, 
or in combination with irinotecan in patients who are refractory to 
irinotecan-based chemotherapy. Due to the important role of the 
EGFR in skin homeostasis, cutaneous reactions are a common 
adverse effect of cetuximab, mainly as acneiform follicular eruption 
seen in almost 85% of patients. We report on a 46-year-old female 
Caucasian patient with metastatic colorectal cancer, referred to 
our department for acneiform eruption induced by cetuximab 
in combination with irinotecan. Four days after the first infusion 
the patient developed intense acneiform eruption consisting of 
erythematous follicular papules and pustules spread to the face, 
neck and upper part of the trunk, accompanied by intense pruritus 
and fever (38.0 °C). There were no comedones. Biopsy specimen 
revealed superficial and florid neutrophilic suppurative folliculitis. 
She was treated with erythromycin tablet 600 mg, three times 
a day for 1 month, and topical clindamycin solution 3%. After 1 
month of treatment, the lesions consistently faded, and the patient 
continued receiving immunochemotherapy. 
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INTRodUCTIoN
 Novel biologically targeted therapies that in-
terfere with specific molecular pathways affecting 
cancer evolution have been developed as poten-
tial treatment options for patients refractory or 
intolerant to conventional chemotherapy (1). The 
epidermal growth factor receptor (EGFR), also 
called HER-1, is a transmembrane glycoprotein 
that binds specific ligands, epidermal growth fac-
tor (EGF) and transforming growth factor-alpha 
(TGF-α), initiating a cascade of intracellular sig-
naling that ultimately regulates cell proliferation, 
migration, adhesion, differentiation and survival. 
The EGFR is constitutively expressed in many 
normal epithelial tissues, including skin and hair 
follicle. Aberrant signaling through the EGFR is 
associated with neoplastic cell proliferation, mi-
gration, stromal invasion, resistance to apoptosis 
and angiogenesis. EGFR is expressed by 30% to 
100% of solid tumors (2). Some tumor cells that 
overexpress this receptor also produce a high 
level of EGFR ligands, creating an autocrine acti-
vation loop that is thought to promote independent 
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tumor growth. Indeed, increased EGFR activity 
has been correlated with worse prognosis in pa-
tients with various types of cancer, including head, 
neck, colorectal, lung, renal and pancreatic can-
cers (3). The chimeric antibody cetuximab alone 
and in combination with irinotecan has shown a 
consistent therapeutic activity in EGFR-expressing 
refractory colorectal cancer (CRC) (4-6). Indeed, 
cetuximab is approved by the US Food and Drug 
Administration for the treatment of EGFR-express-
ing metastatic colorectal cancer as monotherapy 
in patients who are intolerant to irinotecan-based 
chemotherapy, or in combination with irinotecan 
in patients who are refractory to irinotecan-based 
chemotherapy. EGFR inhibitors are generally well 
tolerated and do not have severe systemic side 
effects of cytotoxic drugs. However, due to the im-
portant role of EGFR in skin homeostasis, cuta-
neous reactions are a common adverse effect of 
cetuximab, mainly as acneiform follicular eruption 
seen in almost 85% of patients (7-9). Other less 
frequent dermatological adverse events are xero-
sis, small oral aphthous ulcers, seborrheic derma-
titis-like eruptions, paronychia, desquamation and 
pruritus (10).
CASe RePoRT
 We report on a 46-year-old female Cauca-
sian patient with metastatic CRC, referred to our 
department for acneiform eruption induced by ce-
tuximab in combination with irinotecan. Previuo-
sly, she was unsuccessfully treated with eleven 
cycles of polychemotherapy consisting of fluoro-
uracil/leucovorin plus irinotecan (FOLFIRI), fol-
lowed by eight cycles of another combination of 
chemotherapy (fluorouracil/leucovorin plus oxali-
platin, FOLFOX); however, the lung and liver me-
tastases continued progressing. Capecitabina, a 
third-line chemotherapy, was then administered in 
4 cycles, with no improvement. The last cycle of 
FOLFOX was then administered to the patient as 
the last chance, with no success. Biopsy speci-
men immunophenotyping revealed 10% of neo-
plastic cells to be EGFR positive. Therefore, the 
patient underwent a first cycle of intravenous im-
munochemotherapy with cetuximab 600 mg (400 
mg/m2) and irinotecan 290 mg (180 mg/m2). Four 
days after this first infusion, the patient developed 
intense acneiform eruption consisting of erythem-
atous follicular papules and pustules spread to the 
face, neck and upper part of the trunk, accompa-
nied by severe pruritus and fever (38.0 °C) (Fig. 
1A). There were no comedones. Biopsy specimen 
revealed superficial and florid neutrophilic suppu-
rative folliculitis. A dense monomorphic infiltrate of 
neutrophils and eosinophils was constantly dis-
tributed around the infundibula (Fig. 1B). She was 
treated with erythromycin tablet 600 mg, three 
Figure 1. (A) Erythematous follicular papules and pustules; (B) Superficial and florid neutrophilic suppura-
tive folliculitis with a dense monomorphic infiltrate of neutrophils and eosinophils around the infundibula.
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times a day for 1 month, and topical clindamycin 
solution 3%. After 1 month of treatment, the le-
sions consistently faded and the patient continued 
receiving immunochemotherapy. Eight months af-
ter cetuximab/irinotecan therapy, the progression 
of metastasis was arrested.
dISCUSSIoN
 A classic case of acneiform eruption in a fe-
male patient receiving cetuximab for metastatic 
CRC resistant to conventional chemotherapy is 
reported. Acneiform eruption is a common side ef-
fect of EGFR inhibitors as biological drugs, which 
is observed in 75%-100% of patients. The erup-
tion is generally confined to the seborrheic areas, 
shoulders and upper trunk, whereas sometimes it 
may involve the abdomen, buttocks and even the 
arms and legs. The skin lesions consist of itchy 
erythematous follicular papules that may evolve 
into pustules. The pustules may merge into lakes 
of pus that dry out with the formation of yellow 
crusts. The follicular skin lesions are not preceded 
by visible comedones and can therefore not be 
considered as true acne. The acneiform eruption 
arises after a few days up to 1 week of treatment 
and reaches maximum intensity after 2 to 3 weeks 
following the beginning of therapy. Rarely, the 
rash occurs in a delayed way after the first three 
weeks of treatment. Data from a large number of 
clinical trials suggest that there is a relationship 
between the rash incidence and response/survival 
rate, indicating rash as a possible marker of effec-
tive target inhibition and activity of EGFR-targeted 
agents (8,11). Rash does not affect all patients 
and there is a high inter-individual variability. Cur-
rent data indicate that both the onset and sever-
ity of rash are related to drug exposure, although 
its etiology remains unclear. It has been reported 
that EGFR inhibition of keratinocytes in vitro in-
creases the levels of chemoattractants including 
CCL2/MCP-1, CCL5/RANTES, CXCL10/IFN-γ-in-
ducible protein/10 leading to stronger recruitment 
of inflammatory cells, possibly favoring cutaneous 
pustular reactions (12). Clear guidelines for rash 
management are warranted, since cetuximab is to 
be largely and for longer periods used in the near 
future.
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